Results 31 to 40 of about 895 (134)
Retinal Toxicity of Intravitreal Injection of Ziv-Aflibercept in Albino Rabbits. [PDF]
Transl Vis Sci Technol, 2018 To evaluate retinal toxicity of ziv-aflibercept, a drug that had been approved for use for patients with colon cancer.Twenty-two albino rabbits were injected intravitreally with 0.1 mL of ziv-aflibercept solution into the experimental eye and 0.1-mL saline into the control eye. Twelve were used for electroretinogram (ERG) at 4-weeks follow-up.
Ramon D +5 more
europepmc +3 more sources
FOLFOX plus ziv‐aflibercept or placebo in first‐line metastatic esophagogastric adenocarcinoma: A double‐blind, randomized, multicenter phase 2 trial [PDF]
Cancer, 2019 , James Cleary
exaly +2 more sources
Toxicology Reports, 2023 Sulfur mustard (SM)-induced ocular injury is characterized by an acute inflammatory response that may become chronic or enter a latent phase with delayed pathology.
Ariel Gore +6 more
doaj +1 more source
Comprehensive biophysical and functional study of ziv-aflibercept: characterization and forced degradation. [PDF]
Sci Rep, 2020 AbstractAflibercept (AFL) is an Fc fusion protein used in the treatment of colorectal cancers and different ophthalmological diseases. There are two medicines in which AFL is the active substance: Zaltrap and Eylea, referred as ziv-AFL and AFL respectively. No proper accelerated degradation studies were published on either AFL or ziv-AFL. These studies
Hermosilla J +6 more
europepmc +7 more sources
Thoracic Cancer, Volume 14, Issue 8, Page 779-782, March 2023., 2023 Small cell lung cancer patients presenting with metastasis of the iris are rare. Here, we report an extensive stage small cell lung cancer patient who presented with iris metastasis in the right eye and metastasis in the left adrenal gland as disease progression to first‐line chemotherapy plus atezolizumab.
Zhe Huang, Yongchang Zhang
wiley +1 more source
The Inflation Reduction Act: A boon for the generic and biosimilar industry
Journal of Clinical Pharmacy and Therapeutics, Volume 47, Issue 11, Page 1738-1751, November 2022., 2022 The Inflation Reduction Act gives a significant boost to generics and biosimilars!Soon lowered out‐of‐pocket costBiosimilars promoted and adopted Abstract What is Known and Objective After more than a year of negotiation, a $740 billion climate and health care bill known as The Inflation Reduction Act (IRA) became law on 16 August 2022.
Sarfaraz K. Niazi
wiley +1 more source
Efficacy and safety of Ziv-aflibercept in patients with central retinal vein occlusion
Delta Journal of Ophthalmology, 2021 Background Retinal vein occlusion is one of the most common vascular disorders that can cause visual loss. It is classified into central retinal vein occlusion (CRVO) and branch retinal vein occlusion.
Amin E Nawar, Heba M Shafik
doaj +1 more source
Retinal pigment epithelium rip following single intravitreal ziv-aflibercept injection
Indian Journal of Ophthalmology, 2018 Sumit Randhir Singh, Jay Chhablani
doaj +2 more sources
Clinical Pharmacology &Therapeutics, Volume 112, Issue 4, Page 782-790, October 2022., 2022 Patients with cancer and advanced hepatic impairment (HI) (i.e., moderate and severe impairment) are often excluded from first‐in‐patient, phase II, and phase III studies. Thus, dose recommendations for this subgroup of patients are often derived using a combination of dedicated phase I studies conducted in participants without cancer and a population ...
Derek Z. Yang +4 more
wiley +1 more source
Clinical management of metastatic colorectal cancer in the era of precision medicine
CA: A Cancer Journal for Clinicians, Volume 72, Issue 4, Page 372-401, July/August 2022., 2022 Abstract Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second most common cause of cancer deaths. Initial clinical presentation as metastatic CRC (mCRC) occurs in approximately 20% of patients. Moreover, up to 50% of patients with localized disease eventually develop metastases.
Fortunato Ciardiello +5 more
wiley +1 more source